These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31902811)

  • 1. [Vascular adverse events of ponatinib during treatment of Philadelphia chromosome-positive leukemia: a retrospective single-institution analysis].
    Sato N; Yuda J; Yamauchi N; Miyamoto K; Kamihara Y; Minami Y
    Rinsho Ketsueki; 2019; 60(12):1623-1629. PubMed ID: 31902811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ponatinib-associated panniculitis: Case report and review of the literature.
    Antwi-Amoabeng D; Ghuman J; Ghuman J; Beutler BD; Ulanja MB; Kuriakose K; Bowman A
    Cancer Treat Res Commun; 2021; 27():100357. PubMed ID: 33756173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Narayanan V; Pollyea DA; Gutman JA; Jimeno A
    Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
    Heiblig M; Rea D; Chrétien ML; Charbonnier A; Rousselot P; Coiteux V; Escoffre-Barbe M; Dubruille V; Huguet F; Cayssials E; Hermet E; Guerci-Bresler A; Amé S; Sackmann-Sala L; Roy L; Sobh M; Morisset S; Etienne G; Nicolini FE
    Exp Hematol; 2018 Nov; 67():41-48. PubMed ID: 30195076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
    Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
    Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
    Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
    Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ponatinib-induced neutrophilic panniculitis.
    Zhang M; Hassan KM; Musiek A; Rosman IS
    J Cutan Pathol; 2014 Jul; 41(7):597-601. PubMed ID: 24602068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.
    Januzzi JL; Garasic JM; Kasner SE; McDonald V; Petrie MC; Seltzer J; Mauro M; Croce K; Berman E; Deininger M; Hochhaus A; Pinilla-Ibarz J; Nicolini F; Kim DW; DeAngelo DJ; Kantarjian H; Xu J; Hall T; Srivastava S; Naranjo D; Cortes J
    J Hematol Oncol; 2022 Jan; 15(1):1. PubMed ID: 34991679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.
    Tojo A; Kyo T; Yamamoto K; Nakamae H; Takahashi N; Kobayashi Y; Tauchi T; Okamoto S; Miyamura K; Hatake K; Iwasaki H; Matsumura I; Usui N; Naoe T; Tugnait M; Narasimhan NI; Lustgarten S; Farin H; Haluska F; Ohyashiki K
    Int J Hematol; 2017 Sep; 106(3):385-397. PubMed ID: 28444644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ponatinib superior to imatinib in Ph
    Sidaway P
    Nat Rev Clin Oncol; 2024 Jul; 21(7):483. PubMed ID: 38806653
    [No Abstract]   [Full Text] [Related]  

  • 12. Ponatinib in the leukemia world: why a reevaluation is necessary for Philadelphia chromosome-positive patients with T315I mutation.
    Goodrich AD
    Expert Rev Hematol; 2014 Oct; 7(5):513-5. PubMed ID: 25199408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group.
    Kodama Y; Sato A; Kato K; Sakaguchi H; Kato M; Kawasaki H; Hiramatsu H; Kato I; Taga T; Shimada H
    Int J Hematol; 2022 Jul; 116(1):131-138. PubMed ID: 35349077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
    Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
    Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response.
    Hamadi A; Grigg AP; Dobie G; Burbury KL; Schwarer AP; Kwa FA; Jackson DE
    Thromb Haemost; 2019 Jul; 119(7):1112-1123. PubMed ID: 31079415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ponatinib reduces viability, migration, and functionality of human endothelial cells.
    Gover-Proaktor A; Granot G; Shapira S; Raz O; Pasvolsky O; Nagler A; Lev DL; Inbal A; Lubin I; Raanani P; Leader A
    Leuk Lymphoma; 2017 Jun; 58(6):1455-1467. PubMed ID: 27733071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Sanford DS; Kantarjian H; O'Brien S; Jabbour E; Cortes J; Ravandi F
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):365-73. PubMed ID: 25764322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
    Caocci G; Mulas O; Abruzzese E; Luciano L; Iurlo A; Attolico I; Castagnetti F; Galimberti S; Sgherza N; Bonifacio M; Annunziata M; Gozzini A; Orlandi EM; Stagno F; Binotto G; Pregno P; Fozza C; Trawinska MM; De Gregorio F; Cattaneo D; Albano F; Gugliotta G; Baratè C; Scaffidi L; Elena C; Pirillo F; Scalzulli E; La Nasa G; Foà R; Breccia M
    Hematol Oncol; 2019 Aug; 37(3):296-302. PubMed ID: 30892724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan.
    Takahashi N; Kondo T; Ikari Y; Fukumoto Y; Hatake K; Masunari A; Nishibayashi S; Kageyama A; Fukuta Y; Tojo A
    Jpn J Clin Oncol; 2024 Aug; 54(8):930-938. PubMed ID: 38747937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia.
    Tachibana T; Koyama S; Andou T; Ishiyama Y; Tanaka M; Nakajima H; Kanamori H
    Int J Hematol; 2019 Feb; 109(2):162-168. PubMed ID: 30511314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.